SDIX Collaborates With Banyan Biomarkers in Work to Detect Traumatic Brain Injury

SDIX Collaborates With Banyan Biomarkers in Work to Detect Traumatic Brain Injury
July 20, 2010

Newark, DE (July 20, 2010) - SDIXTM (Strategic Diagnostics Inc. d/b/a SDIX, NASDAQ: SDIX), today announced a multi-year collaboration with Banyan Biomarkers, Inc. to provide products and services for Banyan's biomarker discovery work in the detection of traumatic brain injury (TBI). 


The partnership calls for SDIX to collaborate with Banyan on the development of antibodies and immuno-solutions that include:

custom monoclonal and polyclonal antibody development

cell line banking and cryostorage

antibody production and purification - in vivo and in vitro

Dr. Walid Qoronfleh, SDIX Executive Director, Life Sciences, said, "We look forward to working with Banyan Biomarkers as they continue their breakthrough work addressing the unmet clinical needs for detecting TBI. We believe our twenty years of experience in providing immuno-solutions; from antibody to assay development, as well as our in vitro diagnostics expertise make SDIX a valuable partner for companies like Banyan."

Mr. Fran DiNuzzo, SDIX President and CEO said, "We appreciate the opportunity to collaborate on this critical biomarker project with Banyan to help save and improve the lives of patients with brain injuries, including the potential of helping the brave men and women serving in our armed forces." 

"We look forward to working with SDIX on the development of antibodies and immuno-solutions," stated Jackson Streeter, MD, CEO of Banyan Biomarkers.  "This is an important step in the discovery of diagnostics and treatments for TBI and other neurological disorders."

According to the Centers for Disease Control (CDC), at least 1.7 million suffer a traumatic brain injury (TBI) in the United States annually.  That's more than the number diagnosed with the top five cancers combined according to National Cancer Institute (NCI) statistics.  Of those individuals, about 52,000 die, 275,000 are hospitalized, and 1.365 million are treated and released from an emergency department.  The International Brain Injury Association (www.internationalbrain.org)  reports 5.3 million Americans are living today with disabilities related to TBI. 

 

About Banyan Biomarkers (www.banyanbio.com )
Banyan Biomarkers is the leader in developing in vitro diagnostic products to address unmet clinical needs for the detection of traumatic brain injury. The Company is focused on developing a simple point-of-care blood test that will be used by physicians to detect the presence and severity of brain trauma and improve the medical management of head injured patients. Banyan Biomarkers has a licensing agreement with the University of Florida for exclusive global use of technology related to this product. To learn more visit http://www.banyanbio.com .


  About SDIX
SDIX is a biotechnology company, expert at creating advantage by providing a broad
range of quality, innovative and effective immuno-solutions to the Pharmaceutical,
Biotechnology, Diagnostics, and Food Safety markets. For 20 years, SDIX has
developed antibodies which advance its customers' immuno-based work - reducing
time, labor, and costs while increasing accuracy and reliability of results.

SDIX offers a full suite of integrated immuno-solution capabilities including assay
design, development, and production. In life science markets, SDIX capabilities are
being used to help discover the mechanisms of disease, facilitate the development of
new drugs, and provide mechanisms for rapid diagnosis. For more information, visit
www.sdix.com.

Media Contact
Glenn Frantz
Director, Communications
SDIX
111 Pencader Drive
Newark, DE  19702
www.sdix.com
 
302-456-6789 (x 21345)
302-463-0625 (cell)
[email protected]

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.